Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)

被引：0
作者：
Kaku, Kohei
Rasmussen, Mads
Katayama, Yasuyuki
Seino, Yutaka
机构：
来源：
DIABETES | 2009年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A144 / A144
页数：1
相关论文
共 50 条
[31]   Safety, tolerability, pharmacokineties and pharmacodynamics of the once-daily GLP-1 analogue liraglutide in healthy Japanese subjects [J].
Irie, Shin ;
Matsumura, Yoriko ;
Zdravkovic, Milan ;
Jacobsen, Lisbeth V. ;
Kageyama, Shigeru .
DIABETES, 2007, 56 :A540-A540
[32]   Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass [J].
Meier, J. J. ;
Vilsboll, T. ;
Donsmark, M. ;
Hartvig, H. ;
Nauck, M. A. .
DIABETOLOGIA, 2011, 54 :S322-S322
[33]   The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients [J].
Anne Flint ;
Christoph Kapitza ;
Charlotte Hindsberger ;
Milan Zdravkovic .
Advances in Therapy, 2011, 28 :213-226
[34]   The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients [J].
Flint, Anne ;
Kapitza, Christoph ;
Hindsberger, Charlotte ;
Zdravkovic, Milan .
ADVANCES IN THERAPY, 2011, 28 (03) :213-226
[35]   Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide (vol 36, pg 843, 2012) [J].
Astrup, A. ;
Carraro, R. ;
Finer, N. ;
Harper, A. ;
Kunesova, M. ;
Lean, M. E. J. ;
Niskanen, L. ;
Rasmussen, M. F. ;
Rissanen, A. ;
Roessner, S. ;
Savolainen, M. J. ;
Van Gaal, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2013, 37 (02) :322-322
[36]   Liraglutide, a Once-Daily Human GLP-1 Analog, Reverses Indices of Prediabetes in Obese Subjects: A Randomized Placebo-Controlled 20-Week Trial [J].
Finer, Nick ;
Al Hakim, Mazin ;
Astrup, Arne ;
Harper, Angela ;
Lean, Mike ;
Niskanen, Leo ;
Rasmussen, Mads F. ;
Rissanen, Aila ;
Roessner, Stephan ;
Van Gaal, Luc .
DIABETES, 2009, 58 :A443-A444
[37]   Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide [J].
A Astrup ;
R Carraro ;
N Finer ;
A Harper ;
M Kunesova ;
M E J Lean ;
L Niskanen ;
M F Rasmussen ;
A Rissanen ;
S Rössner ;
M J Savolainen ;
L Van Gaal .
International Journal of Obesity, 2012, 36 :890-890
[38]   Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride both as add-on to metformin [J].
Frid, Anders ;
Nauck, Michael A. ;
Hermansen, Kjeld ;
Kolotkin, Ronette L. ;
Hammer, Mette ;
Zdrav-Kovic, Milan ;
Matthews, David .
DIABETES, 2008, 57 :A574-A575
[39]   Liraglutide, a Once-Daily Human GLP-1 Analog, Reduces Systolic Blood Pressure with Minimal Impact from Weight Loss in Subjects with Type 2 Diabetes. [J].
Henry, R. R. ;
Fonseca, V. ;
Tabanera y Palacios, R. ;
Brett, J. ;
Plutzky, J. .
ENDOCRINE REVIEWS, 2010, 31 (03)
[40]   The once-daily human GLP-1 analog liraglutide substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline [J].
Nauck, Michael ;
Brandle, Michael ;
Vaag, Allan ;
Colagiuri, Stephen ;
Schmitz, Ole ;
Zdravkovic, Milan ;
Hermansen, Kyeld .
DIABETES, 2008, 57 :A594-A594
12345